huahaipharm(SH:600521)2016-10-27 16:00Financial Performance - Net profit attributable to shareholders increased by 14.87% to CNY 385,322,856.45 for the first nine months of the year[7]. - Operating revenue for the first nine months reached CNY 2,922,403,480.52, reflecting a growth of 20.66% year-on-year[7]. - Basic earnings per share rose by 15.15% to CNY 0.38[7]. - The weighted average return on equity increased by 0.2 percentage points to 10.18%[7]. - Net profit for Q3 2016 was ¥123,209,209.32, representing an 18.6% increase from ¥103,779,792.48 in Q3 2015[30]. - Total profit for Q3 was ¥169.06 million, compared to ¥181.99 million in the same quarter last year, reflecting a decrease of 7.9%[34]. - Net profit for the first nine months (January-September) was ¥426.92 million, up 9.4% from ¥390.25 million year-on-year[35]. Assets and Liabilities - Total assets increased by 20.96% to CNY 6,671,686,720.72 compared to the end of the previous year[7]. - Total liabilities reached CNY 2,422,499,833.12, compared to CNY 1,795,142,089.28 at the start of the year, which is an increase of approximately 35.00%[22]. - The company's equity attributable to shareholders rose to CNY 4,037,241,345.51 from CNY 3,591,106,762.11, reflecting an increase of about 12.43%[22]. - The company’s total assets reached ¥5,910,335,288.39 as of Q3 2016, compared to ¥4,955,616,487.02 in Q3 2015, reflecting a growth of 19.3%[27]. Cash Flow - Net cash flow from operating activities surged by 356.51% to CNY 330,442,799.46 compared to the same period last year[7]. - Cash flow from operating activities generated ¥330.44 million in the first nine months, significantly higher than ¥72.38 million in the same period last year[38]. - Operating cash flow for the first nine months of 2016 was CNY 400,879,765.88, an increase of 64.3% compared to CNY 244,177,598.36 in the same period last year[41]. - Total cash inflow from operating activities reached CNY 2,108,332,460.78, up from CNY 1,781,765,679.51, reflecting a growth of 18.4%[41]. - The company reported a net increase in cash and cash equivalents of CNY 184,692,852.01, down from CNY 286,362,135.29 year-over-year[42]. Expenses - Sales expenses rose by 32.77% to ¥395,470,802.99, mainly due to increased marketing efforts for formulation products[13]. - Management expenses increased by 37.46% to ¥587,376,393.97, primarily due to higher R&D costs and personnel expenses[13]. - The company’s tax expenses for Q3 were ¥27.59 million, significantly higher than ¥11.96 million in the same quarter last year, indicating a rise of 130.9%[34]. Shareholder Information - The total number of shareholders reached 14,711 at the end of the reporting period[10]. - The top shareholder, Chen Baohua, holds 26.76% of the shares, amounting to 275,918,890 shares[10]. Government and Other Income - Government subsidies recognized in the first nine months amounted to CNY 45,642,808.32[8]. - The company reported a 140.17% increase in other income to ¥48,592,550.87, primarily from increased government subsidies[13]. - Non-recurring gains and losses for the first nine months totaled CNY 33,575,696.81[8]. Investments and Financing - The company completed a non-public issuance of A-shares, approved by the China Securities Regulatory Commission, to enhance capital[15]. - The company’s investment income decreased by 69.66% to ¥475,405.67, mainly due to reduced financial investment returns[13]. - Cash outflow from investing activities was CNY 1,189,621,516.88, slightly down from CNY 1,228,751,091.70, indicating a decrease of 3.2%[41].